Macrophage–Tip EC Crosstalk in Proliferative Diabetic Retinopathy: An HLA-DRA/RNF130–TP53INP1 Axis

In the delicate landscape of the human eye, a network of tiny blood vessels delivers oxygen and nutrients to the retina, the light-sensitive tissue at the back that allows us to see. When diabetes damages these vessels, the eye reacts by trying to grow new ones, a desperate attempt to restore blood flow. However, in a severe form of the disease known as proliferative diabetic retinopathy, this repair mechanism goes wrong. Instead of forming healthy, organized vessels, the eye produces fragile, chaotic new blood vessels that are accompanied by thick, scar-like tissue. This combination of abnormal growth and scarring can lead to bleeding inside the eye and the retina peeling away from the back of the eye, causing blindness. While doctors currently use injections to block the signals that tell blood vessels to grow, this treatment often fails to stop the scarring, leaving patients with a difficult choice between vision loss and repeated medical procedures. The missing piece of the puzzle has been understanding how the immune system and the blood vessels talk to each other to create this specific mix of new vessels and scar tissue.

A researcher at Jinan University and a hospital in Jiangmen, China, set out to decode this conversation. They focused on two specific groups of cells that meet at the leading edge of this abnormal growth: macrophages, which are immune cells that patrol the body and release chemical signals, and tip endothelial cells, which are the specialized leaders of the new blood vessels, guiding them forward like scouts. The researcher wanted to find out which specific genes in these cells drive the formation of the scar tissue and whether they could find a way to stop it. By combining data from thousands of patients with advanced computer simulations, they constructed a detailed map of how these two cell types influence one another.

The study began by sifting through vast amounts of genetic data from patients with the disease to identify the most likely culprits. Using a method that treats genetic variations as natural experiments to determine cause and effect, the researcher narrowed down thousands of potential genes to a small, critical group. They found that three specific genes were consistently active in the disease state. Two of these genes, HLA-DRA and RNF130, were found to be active in the macrophages, while a third gene, TP53INP1, was active in the tip endothelial cells. This suggested a direct line of communication: the immune cells were sending instructions to the blood vessel leaders, and these three genes were the key players in that exchange.

To understand what these genes were actually doing, the researcher used a powerful computer tool to simulate what would happen if they turned these genes on or off. When they simulated turning off the two genes in the macrophages, the immune cells lost their identity and began acting like a different type of cell entirely. This indicated that these genes are essential for keeping the macrophages in their proper state. Conversely, when they simulated turning on these genes, the macrophages became highly active, releasing a flood of chemical signals. One of the most important signals they identified was a molecule called NAMPT. The researcher found that this molecule acts as a bridge, connecting the immune cells to the blood vessel cells. It binds to receptors on the tip endothelial cells, telling them to start rearranging the structural framework around them, a process that leads to the formation of the problematic scar tissue.

The researcher then looked for a way to interrupt this harmful conversation. They used artificial intelligence to screen thousands of existing drugs to see if any could bind to the three key genes they had identified. They found a promising candidate: a drug called Oracillin, which is already approved by the Food and Drug Administration for use as an antibiotic. Computer models showed that Oracillin fits well into the structures of all three target genes, suggesting it could potentially block the signals from the immune cells and stop the blood vessel cells from building scar tissue. The researcher noted that while this drug is currently used to fight bacteria, its chemical structure might allow it to calm down the immune system in the eye without the need for new, untested medications.

The study concludes by proposing a clear model of how the disease progresses: macrophages, driven by HLA-DRA and RNF130, release signals like NAMPT that instruct tip endothelial cells to remodel their environment through the gene TP53INP1, resulting in the fibrous membranes that cause blindness. While the findings are currently based on computer simulations and genetic data analysis, they provide a concrete roadmap for future experiments. The researcher suggests that the next step is to test this theory in living cells and animal models to see if blocking this specific pathway can prevent the formation of scar tissue. If successful, this approach could offer a new way to treat the disease that targets the root cause of the scarring, rather than just the blood vessel growth, potentially saving vision for millions of people with diabetes.